Oncogenes.

R Todd; D T Wong

PubMed · 10697588

Oncogenes.

Abstract

Oncogenes are gain-of-function mutations of normal regulatory genes or proto-oncogenes. Originally discovered in retroviruses initiating a variety of animal and avian cancers, oncogenes are believed to be important contributors to human carcinogenesis. Proto-oncogenes are altered by point mutation, amplification or rearrangement. Structural alteration of proto-oncogenes leads to a quantitative or qualitative expression change of the corresponding protein product. Oncoproteins subvert signal transduction pathways at the cell surface, in the cytosol and/or in the nucleus. Together with other oncoproteins or in the absence of tumor suppressor gene products, oncogenes contribute to human cancer formation by supporting accelerated proliferation, de-regulating cell cycle control or blocking apoptosis.

Explore related subjects

Cell Transformation, Neoplastic Humans Oncogenes Retroviridae Journal Article Review

Keep this discovery

Explore connections, maps & timelines

BibTeX RIS

R Todd, D T Wong. Oncogenes.. https://pubmed.ncbi.nlm.nih.gov/10697588/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2001

STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma.

A characteristic feature of neoplastic transformation is the loss of external control by cytokines and extracellular matrix of cellular differentiation, migration, and mitogenesis. Because suppressors of cytokine signaling (SOCS) proteins are negative regulators of cytokine-induced signaling, it has been hypothesized that an aberrant SOCS expression plays a role in neoplastic transformation. This study reports on a constitutive SOCS-3 expression in cutaneous T-cell lymphoma (CTCL) cell lines. SOCS-3 protein is constitutively expressed in tumor cell lines (but not in nonmalignant T cells) obtained from affected skin from a patient with mycosis fungoides (MF) and from peripheral blood from a patient with Sezary syndrome (SS). In contrast, constitutive SOCS-3 expression is not found in the leukemic Jurkat T-cell line, the MOLT-4 acute lymphoblastic leukemia cell line, and the monocytic leukemic cell line U937. Expression of SOCS-3 coincides with a constitutive activation of STAT3 in CTCL tumor cells, and stable transfection of CTCL tumor cells with a dominant negative STAT3 strongly inhibits SOCS-3 expression, whereas transfection with wild-type STAT3 does not. Moreover, the reduced SOCS-3 expression in cells transfected with the dominant negative STAT3 is associated with an increased sensitivity to interferon-alpha (IFN-alpha). In conclusion, evidence is provided for a constitutive SOCS-3 expression in cancer cells obtained from patients with CTCL. Moreover, the findings indicate that the aberrant expression of SOCS-3 is mediated by a constitutive activation of STAT3 in CTCL cells and affects the IFN-alpha sensitivity of these cells. (Blood. 2001;97:1056-1062)

Cell Transformation, Neoplastic↗

PubMed2001

Molecular markers of tumor initiation and progression.

Of the hundreds of genes and proteins reported to be altered in human cancers, only a few are sufficiently central to warrant translation into diagnostic or therapeutic tools. Three recent developments have the potential to alter radically the discovery of molecular markers: the compendium of human genes; the advent of technologies that provide the means to identify simultaneously several known and unknown genes and proteins; and an appreciation of the critical processes involved in tumor initiation and progression.

Cell Transformation, Neoplastic↗

PubMed2001

The transforming growth factor-beta signaling pathway in tumorigenesis.

Transforming growth factor-beta is believed to play a dual role in carcinogenesis. Through its ability to inhibit cellular proliferation it suppresses tumor development in its early stages, but in the course of tumor progression malignant cells often acquire resistance to growth inhibition by transforming growth factor-beta and themselves secrete large amounts of this cytokine. Transforming growth factor-beta furthers malignant progression in two ways: for one, it acts on nontransformed cells present in the tumor mass to suppress antitumor immune responses and to augment angiogenesis. Secondly, it promotes invasion and the formation of metastases in a cell-autonomous manner that requires transforming growth factor-beta signaling activity, albeit at reduced levels, to be present in the tumor cells themselves.

Cell Transformation, Neoplastic↗